Welcome to Multibagg AI
Log in to access personalized features
Bearish
2
Neutral
7
Bullish
5
Bearish
16
Neutral
7
Bullish
23
Bearish
14
Neutral
0
Bullish
18
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
688.00 | 392 Cr | 40.88 | 0.99 | 0.73 | -3.83 | -3.33 | 1.80 | |
100.60 | 389 Cr | 27.12 | 1.84 | 0.00 | 7.41 | 11.89 | 3.14 | |
1295.00 | 385 Cr | 19.72 | 1.87 | 0.12 | 9.06 | 12.31 | 5.32 | |
68.10 | 367 Cr | 47.30 | 1.28 | 0.00 | 2.62 | 6.18 | 1.50 | |
291.00 | 361 Cr | — | 2.24 | 0.00 | — | — | 0.00 | |
43.50 | 354 Cr | 31.07 | 5.29 | 0.00 | 16.97 | 20.65 | 8.44 | |
240.00 | 320 Cr | 11.57 | 3.39 | 0.77 | 12.57 | 13.83 | 7.53 |
Investor Presentation
Q4 FY25
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
SMS Lifesciences India Limited is primarily involved in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and their intermediates. The company operates multiple facilities across Hyderabad.
Originally incorporated as a real estate private limited company in 2006, SMS Lifesciences has undergone several transformations, including demergers and acquisitions.
The company holds significant recognition as an export house since 1997, indicating expertise in global pharmaceutical supply chains.
With three multi-product facilities and a research center, SMS Lifesciences engages in contract manufacturing and research assignments for an international clientele.
A strategic demerger in 2017 positioned the company to leverage semi-regulated units, enhancing its manufacturing capabilities and international market reach.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
385 Cr
Moderate Risk
19.7
28.4
0.1
1.9
1,680.00
956.05
Sales CAGR
Profit CAGR
ROE
ROCE
Haleos Labs Limited (HALEOSLABS) is currently trading at 1,295.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
SMS Lifesciences India Limited is primarily involved in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and their intermediates. The company operates multiple facilities across Hyderabad. Originally incorporated as a real estate private limited company in 2006, SMS Lifesciences has undergone several transformations, including demergers and acquisitions. The company holds significant recognition as an export house since 1997, indicating expertise in global pharmaceutical supply chains. With three multi-product facilities and a research center, SMS Lifesciences engages in contract manufacturing and research assignments for an international clientele. A strategic demerger in 2017 positioned the company to leverage semi-regulated units, enhancing its manufacturing capabilities and international market reach.
Over the past 52 weeks, Haleos Labs Limited has traded between a low of ₹956.05 and a high of ₹1,680.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Haleos Labs Limited has a market capitalization of approximately 385.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Haleos Labs Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.72 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 385.47 Cr, Haleos Labs Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Haleos Labs Limited operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Haleos Labs Limited is 19.72. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Special Window - Share Transfer
Haleos Labs informs shareholders that, pursuant to SEBI circular dated Jan 30, 2026, a special window is reopened from Feb 5, 2026 to Feb 4, 2027 for re‑lodgement of physical transfer requests lodged before Apr 1, 2019; transfers will be processed only in demat form and locked for one year.
Corporate Action
Haleos Labs reopens SEBI‑mandated special window (Feb 5, 2026–Feb 4, 2027) for re‑lodgement of physical share transfer requests lodged before Apr 1, 2019; transfers will be processed only in demat form and locked for 1 year; contact RTA Aarthi Communication.
